HLS THERAPEUTICS INC (HLS.CA) Forecast, Price Target & Analyst Ratings
TSX:HLS • CA40390B1094
4.39 CAD
-0.01 (-0.23%)
Last: Mar 4, 2026, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HLS THERAPEUTICS INC (HLS.CA).
Forecast Snapshot
Consensus Price Target
CA$8.35
+ 90.23% Upside
Next Earnings Forecast
Release DateMar 12, 2026
PeriodQ4 / 2025
EPS Estimate-$0.03
Revenue Estimate15.15M
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
CA$8.35
Upside
+ 90.23%
From current price of CA$4.39 to mean target of CA$8.35, Based on 8 analyst forecasts
Low
CA$4.80
Median
CA$8.16
High
CA$12.60
Price Target Revisions
1 Month
0.00%
3 Months
21.30%
Price Target Summary
8 analysts have analysed HLS.CA and the average price target is 8.35 CAD. This implies a price increase of 90.23% is expected in the next year compared to the current price of 4.39.
The average price target has been revised upward by 21.3% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
HLS.CA was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about HLS.CA.
In the previous month the buy percentage consensus was at a similar level.
HLS.CA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-11 | Stifel Nicolaus Research | Downgrade | |
| 2022-10-26 | Stifel Nicolaus Research | Maintains | Buy |
| 2022-08-25 | Raymond James Capital | Downgrade | Outperform |
| 2022-08-12 | Stifel Nicolaus Research | Downgrade | |
| 2022-05-06 | Raymond James Capital | Initiate | Outperform |
| 2022-04-27 | Clarus Securities | Reiterate | Buy |
| 2022-04-27 | Raymond James Capital | Upgrade | Outperform |
| 2022-03-21 | Clarus | Initiate | Buy |
| 2022-03-20 | Raymond James Capital | Initiate | Outperform |
| 2022-03-20 | Canaccord Capital | Downgrade | Buy |
| 2022-03-15 | Raymond James Capital | Initiate | Outperform |
| 2022-03-10 | Stifel Nicolaus Research | Initiate | Buy |
| 2021-12-16 | Raymond James Financial | Initiate | Outperform |
| 2021-11-05 | RJ Financial | Initiate | Outperform |
| 2021-10-28 | Raymond James Financial | Initiate | Outperform |
| 2021-08-17 | Raymond James Financial | Upgrade | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 12, 2026
PeriodQ4 / 2025
EPS Estimate-$0.03
Revenue Estimate15.15M
Revenue Q2Q-2.52%
EPS Q2Q69.70%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
HLS.CA is expected to report earnings on 3/12/2026. The consensus EPS estimate for the next earnings is -0.03 CAD and the consensus revenue estimate is 15.15M CAD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 61.5M 2.50% | 63.074M 2.56% | 56.619M -10.23% | 55.516M -1.95% | 62.216M 12.07% | 69.337M 11.45% | 66.913M -3.50% | 71.649M 7.08% | 75.346M 5.16% | |
| EBITDA YoY % growth | 20.9M -13.13% | 20.129M -3.69% | 13.523M -32.82% | 19.661M 45.39% | 22.675M 15.33% | 25.705M 13.36% | 34.542M 34.38% | 40.4M 16.96% | 45.955M 13.75% | |
| EBIT YoY % growth | -13.5M -117.74% | -11.81M 12.52% | -9.194M 22.15% | -4.949M 46.17% | -1.01M 79.59% | 3.939M 490.00% | 10.302M 161.54% | 16.16M 56.86% | 21.715M 34.38% | |
| Operating Margin | -21.95% | -18.72% | -16.24% | -8.91% | -1.62% | 5.68% | 15.40% | 22.55% | 28.82% | |
| EPS YoY % growth | -0.59 -43.90% | -0.85 -44.07% | -0.62 27.06% | -0.39 36.47% | -0.22 43.59% | -0.05 77.27% | 0.14 380.00% | 0.32 128.57% | 0.51 56.25% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.03 69.70% | -0.08 42.29% | -0.05 43.89% | -0.05 57.92% | -0.04 -33.33% |
| Revenue Q2Q % growth | 15.15M -2.52% | 13.13M 4.02% | 16.16M 14.04% | 16.16M 19.61% | 17.17M 13.33% |
| EBITDA Q2Q % growth | 5.824M -73.61% | 4.949M 72.26% | 5.858M -41.62% | 6.06M -58.05% | 6.363M 9.25% |
| EBIT Q2Q % growth | -505K 21.58% | -1.111M 55.33% | -202K 75.03% | 100.00% | 303K 160.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.26%
EPS Next 5 Year
20.32%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
6.49%
Revenue Next 5 Year
4.53%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
64.45%
EBIT Next 5 Year
42.36%
HLS THERAPEUTICS INC / HLS.CA Forecast FAQ
What do analysts expect the price target to be for HLS THERAPEUTICS INC (HLS.CA)?
8 analysts have analysed HLS.CA and the average price target is 8.35 CAD. This implies a price increase of 90.23% is expected in the next year compared to the current price of 4.39.
What is the next earnings date for HLS stock?
HLS THERAPEUTICS INC (HLS.CA) will report earnings on 2026-03-12, after the market close.
What are the consensus estimates for HLS stock next earnings?
The consensus EPS estimate for the next earnings of HLS THERAPEUTICS INC (HLS.CA) is -0.03 CAD and the consensus revenue estimate is 15.15M CAD.
How many analysts have analysed HLS THERAPEUTICS INC (HLS.CA)?
The number of analysts covering HLS THERAPEUTICS INC (HLS.CA) is 8.